NOROCARP 50 MG TABLETS VETERINARY

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

CARPROFEN

Verfügbar ab:

COMEX LTD

Darreichungsform:

TABLETS

Zusammensetzung:

CARPROFEN 50 MG

Verabreichungsweg:

PER OS

Verschreibungstyp:

Required

Hergestellt von:

NORBROOK LABORATORIES LIMITED, NORTHERN IRELAND

Anwendungsgebiete:

In dogs: Reduction of inflammation and pain caused by muscoskeletal disorders and degenerative joint disease.As a follow up to parenteral analgesia in the management of post operative pain.

Berechtigungsdatum:

2021-12-31

Gebrauchsinformation

_SUMMARY OF PRODUCT CHARACTERISTICS _
_VETERINARIAN PRESCRIPTION ONLY MEDICINE _
_FOR ANIMAL USE ONLY _
1.
NAME FORM AND STRENGTH OF THE VETERINARY MEDICIN
Norocarp 20 mg tablets veterinary
Norocarp 50 mg tablets veterinary
Norocarp 100 mg tablets veterinary
2.
ACTIVE INGREDIENTS
Each 20 mg tablet contains: Carprofen 20mg
Each 50 mg tablet contains: Carprofen 50mg
Each 100mg tablet contains: Carprofen 100ng
Norocarp 100mg tablets contains T
artrazine (E102)
1.2 mg
For a full list of excipients, see section 12 “further
information”
3.
INDICATIONS FOR USE
In Dogs: Reduction of inflammation and pain caused by muscoskeletal
disorders and
degenerative joint disease.
As a follow up to parenteral analgesia in the management of
post-operative pain.
THERAPEUTIC GROUP:
Non steroidal
anti inflammatory drug (NASID)
4.
CONTRAINDICATIONS
Do not use in cats.
Do not exceed the stated dose.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of
gastrointestinal ulceration or bleeding, or where there is evidence of
a blood dyscrasia.
Do not use in animals with known hypersensitivity to the active
substance or to any of the
excipients.
5.
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Typical undesirable effects associated with NSAIDs such as vomiting,
soft
faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy
have been
reported. These adverse reactions occur generally within the first
treatment week and
are in most cases transient and disappear following termination of the
treatment but in
very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and
the advice of a
veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic
hepatic adverse
events.
Side effects can be reported to the Ministry of Health by clicking on
the link "Reporting
adverse events due to drug treatment" found on the hom